Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
This dose was selected based on Phase 3 data from the RECONNECT trials, which randomized 1,247 premenopausal women with HSDD to bremelanotide 1.75 mg or placebo over 24 weeks [1]
The same brain pathways that regulate appetite also influence dopamine release, stress response, and executive functionraising questions about whether these medications might address anxiety and attention challenges alongside metabolic goals
Naltrexone has been built into both abstinence and moderation-based approaches, including ones where drinking continues during treatment
N,N'-[Dithiobis[1-[(carboxymethyl)carbamoyl]ethylene]]diglutamine
Eur J Pharmacol 2004;489:139-149
